- Center for Neurosciences and Cell Biology, and Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal (P.H.D., C.d.O., M.C.L.); Center for Cancer Research (CIC-IBMCC; CSIC/USAL) and Department of Medicine, University of Salamanca, Salamanca, Spain (P.H.D., A.O*., M.D.T.);Neurosurgery Service, University Hospital of Salamanca, Salamanca, Spain (P.S., A.O., J.M.G., L.R.); Research Unity and IECSCYL, University Hospital of Salamanca IBSAL, Salamanca, Spain (M.D.T.).
Tumor recurrence remains the major clinical complication of meningiomas, the majority of recurrences occurring among WHO grade I/benign tumors. In the present study, we propose a new scoring system for the prognostic stratification of meningioma patients based on analysis of a large series of meningiomas followed for a median of >5 years.
Tumor cytogenetics were systematically investigated by interphase fluorescence in situ hybridization in 302 meningioma samples, and the proposed classification was further validated in an independent series of cases (n = 132) analyzed by high-density (500K) single-nucleotide polymorphism (SNP) arrays.
Overall, we found an adverse impact on patient relapse-free survival (RFS) for males, presence of brain edema, younger patients (<55 years), tumor size >50 mm, tumor localization at intraventricular and anterior cranial base areas, WHO grade II/III meningiomas, and complex karyotypes; the latter 5 variables showed an independent predictive value in multivariate analysis. Based on these parameters, a prognostic score was established for each individual case, and patients were stratified into 4 risk categories with significantly different (P < .001) outcomes. These included a good prognosis group, consisting of approximately 20% of cases, that showed a RFS of 100% ± 0% at 10 years and a very poor-prognosis group with a RFS rate of 0% ± 0% at 10 years. The prognostic impact of the scoring system proposed here was also retained when WHO grade I cases were considered separately (P < .001).
Based on this risk-stratification classification, different strategies may be adopted for follow-up, and eventually also for treatment, of meningioma patients at different risks for relapse.